Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with (...)
Site référencé: The Economic Times
The Economic Times
Breakout Stocks : How to trade Mazagon Dock, Bharat Dynamics & Bharat Electronics that hit fresh 52-week high ?
18/05/2025
Trump Shrugs Off Netanyahu on Gulf Tour
18/05/2025
FIIs pump Rs 23,778 cr into Indian stocks in May. Is more buying seen ahead ?
17/05/2025
Arvind Fashions reports Rs 17 crore Q4 Loss despite 13.7% YoY revenue growth
17/05/2025
F&O Talk| Nifty eyes further gains after crossing 25k mark : Is 25,600 the next target ? Sudeep Shah weighs in
17/05/2025
Gold is even worse ! What value investor S Naren has to say on most popular asset class
17/05/2025
